CALIXAR team will be present at the online Bio Europe event, from October 25 to 28, 2021 to discuss about commercial and scientific opportunities linked to our activities.
CALIXAR is a biotech company specialized in the identification and isolation of functional membrane therapeutic targets and antigens (GPCRs, Ion channels, Transporters, …). The company is currently investing in the extension of its pipeline of highly druggable membrane protein targets and native antigens. Within the next few years, CALIXAR will be able to offer to Pharma companies native and functional therapeutic targets validated and in a ready-to-discovery format.
CALIXAR wants to become a leader in the early discovery segment of drug development based on complex therapeutic targets (membrane proteins), a market predicted to be worth € 70 bn by 2025.
About Bio Europe:
The international BIO-Europe® 2021 gathering will be held digitally, standing tall in this time of insecurity, to execute on its pivotal role in bringing the global biopharma and investment leaders together to build partnerships that facilitate innovation and medical breakthroughs. BIO-Europe attracts a wide range of business leaders, including senior executives of leading biotech companies, business development teams from large and midsize pharmaceutical companies, investors, and other industry experts.
For more information and meet us: Bio Europe